文献速递前列腺癌

英国最大医疗信托20年回顾分析:黑人与白人转移性去势抵抗性前列腺癌的总生存差异

Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-01-21

该研究基于英国东伦敦2008-2010年数据及1997-2016年425例mCRPC病例,分析黑人与白人患者的生存差异。结果显示黑人mCRPC患者中位总生存为25.5个月对21.8个月(HR=0.81,p=0.08),仅接受激素治疗者黑人组39.7个月对17.1个月(HR=0.54,p=0.019)。在医疗可及性平等背景下,黑人mCRPC患者可能预后更好,且激素治疗获益可能更大。

要点

  • 黑人mCRPC患者中位总生存25.5个月,白人为21.8个月,差异未达统计学显著(HR=0.81,p=0.08)。
  • 仅接受激素治疗者中,黑人组中位生存39.7个月显著优于白人组17.1个月(HR=0.54,p=0.019)。
  • 黑人患者基线血红蛋白更低(p<0.001),但两组基线特征总体可比。

核心结论

  • 在医疗可及性平等的背景下,黑人mCRPC患者可能比白人患者预后更好。
  • 研究提示黑人亚群从激素治疗中获得的获益幅度可能更大。

研究设计与样本

  • 回顾性分析1997-2016年英国圣巴塞洛缪医院425例mCRPC病例,其中黑人103例(24%),其余为白人。
  • 另获取东伦敦2008-2010年前列腺癌发病与死亡数据,来源于英国国家疾病注册服务。

主要发现

  • 东伦敦黑人男性前列腺癌发病率高于白人男性,前列腺癌特异性死亡率与发病率成比例。
  • 全队列中位总生存:黑人25.5个月 vs 白人21.8个月(HR=0.81,p=0.08)。
  • 仅接受激素治疗者中位总生存:黑人39.7个月 vs 白人17.1个月(HR=0.54,p=0.019)。
  • 黑人患者基线血红蛋白更低(p<0.001),其余基线特征两组可比。

临床怎么用

  • 在评估mCRPC患者预后时,应结合种族背景考虑生存差异。
  • 对于黑人mCRPC患者,激素治疗可能带来更大幅度的生存获益。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Prostate cancer in black men is associated with poorer outcomes than their white counterparts. However, most studies reporting this disparity were conducted in localized prostate cancer and primarily in the United States. METHODS: Data regarding prostate cancer incidence and mortality for East London between 2008 and 2010 were obtained from the UK National Disease Registration Service. We further evaluated survival outcomes of 425 cases of mCRPC in St Bartholomew's Hospital, East London, between 1997 and 2016, and analyzed whether ethnicity impacted on responses to different treatment types. RESULTS: The incidence of prostate cancer in black men was higher than white men in East London. Prostate cancer-specific mortality was proportional to incidence based on ethnic groups. In the detailed analysis of 425 patients, 103 patients (24%) were black (B), and the remainder white (W). Baseline characteristics were comparable in both groups, although black patients had a lower baseline hemoglobin (p < 0.001). Median overall survival for the total cohort was 25.5 months (B) vs 21.8 months (W) (hazard ratio (HR) = 0.81, p = 0.08). There was prolonged survival in the black population in those who only received hormone-based treatment throughout their treatment course; 39.7 months (B) vs 17.1 months (W) (HR = 0.54, p = 0.019). CONCLUSION: Black men may do better than white men with mCRPC, in the context of equal access to healthcare. The study also suggests a greater margin of benefit of hormone-based therapy in the black subpopulation.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Ng K, Wilson P, Mutsvangwa K, et al. Overall survival of black and white men with metastatic castration-resistant prostate cancer (mCRPC): a 20-year retrospective analysis in the largest healthcare trust in England. Prostate Cancer Prostatic Dis. 2021. PMID: 33479454. doi:10.1038/s41391-020-00316-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。